Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb

Lara L. Chappell, Ekaterina Dadachova, Diane E. Milenic, Kayhan Garmestani, Chuanchu Wu, Martin W. Brechbiel

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a γ-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic α-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalNuclear Medicine and Biology
Volume27
Issue number1
DOIs
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Chelating Agents
Radioimmunodetection
Isotopes
Ligands
Monoclonal Antibodies
Ions
Radioimmunotherapy
Acids
Single-Photon Emission-Computed Tomography
Radioisotopes
Metals
Proteins

Keywords

  • Lead-203
  • Macrocycles
  • Radioimmunoconjugate
  • Radioimmunoimaging
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. / Chappell, Lara L.; Dadachova, Ekaterina; Milenic, Diane E.; Garmestani, Kayhan; Wu, Chuanchu; Brechbiel, Martin W.

In: Nuclear Medicine and Biology, Vol. 27, No. 1, 01.2000, p. 93-100.

Research output: Contribution to journalArticle

Chappell, Lara L. ; Dadachova, Ekaterina ; Milenic, Diane E. ; Garmestani, Kayhan ; Wu, Chuanchu ; Brechbiel, Martin W. / Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. In: Nuclear Medicine and Biology. 2000 ; Vol. 27, No. 1. pp. 93-100.
@article{918a1ac2c438493eaff4e3ef78333682,
title = "Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb",
abstract = "Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a γ-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic α-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Lead-203, Macrocycles, Radioimmunoconjugate, Radioimmunoimaging, Radioimmunotherapy",
author = "Chappell, {Lara L.} and Ekaterina Dadachova and Milenic, {Diane E.} and Kayhan Garmestani and Chuanchu Wu and Brechbiel, {Martin W.}",
year = "2000",
month = "1",
doi = "10.1016/S0969-8051(99)00086-4",
language = "English (US)",
volume = "27",
pages = "93--100",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb

AU - Chappell, Lara L.

AU - Dadachova, Ekaterina

AU - Milenic, Diane E.

AU - Garmestani, Kayhan

AU - Wu, Chuanchu

AU - Brechbiel, Martin W.

PY - 2000/1

Y1 - 2000/1

N2 - Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a γ-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic α-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb. Copyright (C) 2000 Elsevier Science Inc.

AB - Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a γ-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic α-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb. Copyright (C) 2000 Elsevier Science Inc.

KW - Lead-203

KW - Macrocycles

KW - Radioimmunoconjugate

KW - Radioimmunoimaging

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033954403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033954403&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(99)00086-4

DO - 10.1016/S0969-8051(99)00086-4

M3 - Article

C2 - 10755652

AN - SCOPUS:0033954403

VL - 27

SP - 93

EP - 100

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 1

ER -